

Endovascular closure of MINOCA-caused ventricular septal defect (VSD)

Ivo Spasov Petrov, Zoran Iovan Stankov, Damyan Boychev Boychev , Martina Samardjieva

Cardiology Department, Acibadem City Clinic Cardiovascular Center, Sofia, Bulgaria

Correspondence to Professor Ivo Spasov Petrov; petrovivo@hotmail.com

Accepted 12 April 2021

SUMMARY

Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a rare form of acute myocardial infarction and it is an even rarer cause of ventricular septal defect (VSD). We present a case of successful endovascular closure of post-MINOCA VSD with the use of an atrial septal defect (ASD) occluder. The patient improved from intra-aortic balloon pump dependent to New York Heart Association (NYHA) I in a matter of days. 18-month follow-up period is event free and symptom

BACKGROUND

Ventricular septal defect (VSD) caused by myocardial infarction with non-obstructive coronary arteries (MINOCA) is an extremely rare entity. There is no standard protocol or guideline for action. Numerous advancements in devices and techniques in the field of endovascular medicine have made it a possible alternative to surgery for the treatment for this rare condition. We present, to the best of our knowledge, the first report of endovascular closure of MINOCA-caused VSD.

CASE PRESENTATION

A 78-year old woman presented to our clinic late (48 hours) after chest pain onset, dyspnoea, heart failure NYHA III and rapidly deteriorating haemodynamic. The patient's blood pressure was 100/65 mm Hg, heart rate—130 beats/min, respiratory rate was 20 breaths/min and oxygen saturation was 94% on room air. Physical examination was notable for a grade III/IV systolic murmur at the apex of the heart, propagating towards the left sternal border.

The patient had a history of hypertension stage III, paroxysmal atrial fibrillation and diabetes type II. She had survived an ischaemic stroke 10 years




Figure 2 Emergent angiography. (A–C) No significant stenosis or occlusions are evident in the left coronary artery system. (D) Right coronary artery is clear or significant stenosis or occlusions.




Figure 3 Transesophageal echocardiography (TEE) before the procedure. Echocardiography measured the muscular part of the defect as 7 mm wide at its narrowest point.

ago, total hysterectomy 15 years ago and right kidney resection 17 years ago.

INVESTIGATIONS

On ECG, the patient had a new left bundle branch block with secondary repolarisation changes in all leads (figure 1). Laboratory results were remarkable for creatine kinase (CK) of 246 U/L, CK-MB—48 U/L, troponin I hs—478 ng/L. Transthoracic echocardiography (TTE) showed left ventricle ejection



© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Petrov IS, Stankov ZI, Boychev DB, et al. BMJ Case Rep 2021;14:e242303. doi:10.1136/bcr-2021-242303




Figure 1 ECG on presentation. ST-elevations in $V_1 - V_5$ can be seen in addition to new left bundle branch block, both diagnostic for a myocardial infarction.

Case report



Figure 4 Three-dimensional (3D)-echocardiography before the procedure. The defect was visualised and assessed on 3D echo.



Video 1 Transesophageal echocardiography (TEE) before the procedure. TEE showing marked shunt between the left and right ventricle.




Figure 5 CT scan before the procedure. (A) Size of the ventricular septal defect orifice on the side of the left ventricle. (B) Size of the muscular part of the defect.

fraction (LVEF) of 40%, with septo-apical hypokinesia, IInd degree mitral regurgitation, tricuspid regurgitation grade III and elevated right ventricle systolic pressure of 63 mm Hg. VSD in the low-mid septum was visualised with a size of 7/12 mm. Immediate coronary angiography showed no atherosclerotic obstructive disease, neither dissection, nor coronary spasm (figure 2). Transesophageal echocardiography (TEE) and 3D-Echo were performed (figures 3-4, videos 1 and 2). CT a few days later sized the muscular defect as 0.9 cm wide with height and width of the defect orifice on the side of the left ventricle of 0.83 cm and 2.0 cm, respectively (figure 5). The findings were consistent with VSD caused by MINOCA. In the context of paroxismal atrial fibrillation, we assumed that the MINOCA in our case was caused by coronary embolism. VSD is a rare complication of acute myocardial infarction (AMI) and an even rarer complication of MINOCA (only 10 cases reported to date).



Video 2 Three-dimensional (3D)-echocardiography before the procedure. Ventricular septal defect is visualised.




Figure 6 Left ventriculography before device implantation. Massive shunt between the left and right ventricle is visualised.

DIFFERENTIAL DIAGNOSIS

The differential diagnosis between MINOCA and obstructive AMI can be made only by coronary angiography. Distinguishing acute mitral regurgitation from ventricular septal rupture after AMI is difficult based only on the murmur heard, and the colour flow Doppler echocardiography comes as method of choice.

TREATMENT

Due to the rapidly deteriorating haemodynamics, the patient was transferred to the intensive care unit and an intra-aortic balloon pump (IABP) was placed. Twenty-five days after the initial admission, a percutaneous VSD closure was performed. TEE was used in addition to fluoroscopy during the procedure. Through right radial artery, a left ventriculography was performed in LAO 50/CRA 30 revealing a close to normal global LV systolic function and a large VSD in the low mid muscular portion of the septum with significant left to right shunt (QP/QS measurements of 1.8/1.0) (figure 6, video 3). Using a 4 Fr Multipurpose Glide-Cath catheter (Terumo, Japan) and a 0.035", Angled Radifocus Guide Wire M (Terumo, Japan) the defect was crossed and they



Video 3 Left ventriculography before the device implantation. Massive shunt between the leftand right ventricle is visualised.





Figure 7 Transesophageal echocardiography (TEE) during the procedure. Stable positioning of the atrial septal defect occluder device.

were placed in superior vena cava. The wire was snared with a 25 mm Amplatz Goose Neck snare (Medtronic, USA) and externalised by the right jugular vein access followed by the GlideCath, providing a secure and stable arteriovenous loop (video 4). The wire was exchanged for a 260 cm 0.035" STORQ wire (Cordis, UK). Using this *through-and-through access*, a 7F delivery sheath was introduced through the right jugular vein and positioned in the left ventricle across the VSD a Flex II atrial septal defect (ASD) occluder 29ASD09 (Occlutech, Germany) was introduced. Under both fluoroscopic and TEE guidance, the occluder was advanced across the VSD and intro the left ventricle. After secure positioning, the device was released (figures 7–8,videos 5–8). Final angiography showed immediate almost complete isolation of the VSD (figure 9, video 9).



Video 4 Snaring of the wire. The wire is snared into the jugular vein, securing the arteriovenous loop.




Figure 8 Transesophageal echocardiography (TEE) during the procedure. Drastic reduction of the shunt.




Video 5 Transesophageal echocardiography (TEE) during the procedure. Color-flow Doppler showing decreased shunt size after device placement.

OUTCOME AND FOLLOW-UP

The patient was wined off the IABP on the next day and discharged 7 days later with significantly improved LVEF and clinical condition. She was reclassified from NYHA III to NYHA I. At 18-months follow-up, TTE showed that the device was firmly positioned and the shunt was completely sealed, the LVEF had increased to 62% and the systolic pressure in RV had decreased to 29 mm Hg (figure 10, video 10). The patient had neither problems nor clinical events.

DISCUSSION

A study involving 41 021 patients with myocardial infarction (MI) found that VSD occurred in 0.2% of the cases in the



Video 6 Transesophageal echocardiography (TEE) during the procedure. Echo confirming the position of the device.





Figure 9 Left ventriculography after device implantation. Almost complete isolation of the shunt is visualised.

pre-percutaneous coronary intervention (PCI) era. Mortality at 30 days among those patients was more than 10 times higher than in those without this complication. Patients with VSDs in GUSTO-I (Global Utilization of t-PA and Streptokinase for Occluded Coronary Arteries) selected for surgical repair had better outcomes than those treated medically.¹

Natural history data suggest a 2-month mortality rate of 90% after diagnosis in patients who do not undergo closure of the VSD.² The poor survival rate forced us to make a plan for action. After the Heart team discussion, the patient was deemed too high-risk for open-heart surgery at this moment and the only other available option was endovascular closure of the VSD, awaiting further stabilisation and surgery or conservative treatment. The classical treatment is coronary artery bypass grafting (CABG) plus VSD closure, in our case the CABG was unnecessary and the less invasive endovascular treatment seemed like an appropriate alternative.

MINOCA accounts for average 6% of all AMI cases³ and the occurrence of complications with MINOCA is considered lower than in 'standard' infarction. After meticulous research,



Video 7 Three-dimensional (3D) echo after the procedure. Atrial septal defect occluder device firmly positioned.



Video 8 Three-dimensional (3D) echo color-flow Doppler. Drastically reduced shunt is visualised.



Video 9 Left ventriculography after the device implantation. Almost complete isolation of theshunt is visualised.

we found only 10 published cases of MINOCA-caused VSDs. 4-13 All of them treated surgically with an overall survival rate of 60%. We did not find a case of post-MINOCA VSD treated by percutaneous approach.

Several studies described percutaneous closure of VSD after AMI as an alternative to surgery. ^{14–16} The two largest studies investigating post-AMI VSD closed by percutaneous approach are by Asenza *et al* and Calvert *et al*. They include 40 and 53 patients, respectively. ¹⁴ ¹⁵ The patients in the first study had a




Figure 10 Echocardiography 18 months after the procedure. Atrial septal defect occluder device is firmly positioned in place and no shunt is visualised.



Video 10 Transthoracic echocardiography 18 months after the procedure. Improved left ventricle ejection fraction and complete isolation of the shunt are visualised. atrial septal defect occluder device is firmly positioned in place.

77% survival rate 30-days post VSD closure.¹⁴ In the second study, 58% of the patients survived to discharge. Average midterm follow-up of patients after hospital discharge was for 395 days (first and third quartiles, 63–1522) days, during this time, only 4 patients died.¹⁵

The study by Thiele *et al* included 29 patients with post-AMI VSD immediately treated by percutaneous device closure. Their overall 30-day survival rate was 35%. They showed that successful closure of the defect is not the only factor defining survival. Time to intervention, cardiogenic shock, inotropic support, haemodynamic stability, age and comorbidities were also crucial.¹⁶

Those studies gave us proof that closure of the VSD is technically feasible and could be accomplished with a relatively low risk of major periprocedural complications. The question was when to perform the procedure. Data showed mortality rate after postinfarction VSD closure surgery is as high as 50% with lower rate when surgery is delayed. ¹⁷

A retrospective study performed among 41 patients with post-AMI VSD found that the most important factor determining operative mortality and intrahospital survival is the time from the onset of AMI to surgery. Serpytis *et al* reported a 100% survival rate in patients surgically treated after 3–4 weeks of stabilisation versus 100% mortality in patients having surgery within 10 days from symptoms onset.¹⁸

We decided that delaying the VSD closure until haemodynamic stabilisation and further planning of the procedure would increase our chance of success and patient's chance of survival. This additional time before the device implantation allowed stabilisation of the edges of the defect and scarring of the tissue surrounding the VSD to occur, providing firmer support of the closure device.

CT imaging was used for sizing of the device. We decided that ASD occluder is the best suit for our case because it provides a narrow shaft between the disks, ensuring avoidance of additional tissue damage during the delivery and a big enough disk area to ensure sealing of the defect even in the case of a subsequent enlargement. We considered the device best fitting to our case

Patient's perspective

After the procedure my condition improved dramatically. A month after I was discharged from the hospital I was fully back to my normal life. I consider the procedure life-saving. I will be thankfulto the doctor to the end of my life.

Learning points

- ► The echocardiographic and CT imaging is crucial for the ventricular septal defect (VSD) diagnosis and treatment.
- ► The post-myocardial infarction with non-obstructive coronary arteries (MINOCA) VSD is a rare but potently fatal complication that requires timely diagnosis and efficient treatment.
- ► Endovascular closure of post-MINOCA VSD could be an alternative to surgical treatment.

was Occlutech Flex II ASD occluder 29ASD09 (left atria disc size of 20.5 mm/ right atria disc of 16.5 mm and device waist of 9 mm).

Contributors ISP and ZIS: planning, conduct, conception and design. DBB and MS: reporting, acquisition and interpretation of data.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Damyan Boychev Boychev http://orcid.org/0000-0002-7263-8308

REFERENCES

- 1 Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation 2000;101:27–32.
- 2 LEE WY. Perforation of infarcted interventricular septum. Arch Intern Med 1962;109:731.
- 3 Pasupathy S, Air T, Dreyer RP, et al. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. *Circulation* 2015;131:861–70. doi:10.1161/CIRCULATIONAHA.114.011201
- 4 St Louis P, Rippe JM, Benotti JR, et al. Myocardial infarction with normal coronary arteries complicated by ventricular septal rupture. Am Heart J 1984;107:1259–63.
- 5 Nappi G, De Santo LS, Torella M, et al. Postinfarction ventricular septal defect in a patient without coronary lesions. Ann Thorac Surg 2003;75:1315–7.
- 6 Alexopoulos D, Olympios C, Hahalis G. Postinfarction ventricular septal rupture following thrombolysis: long-term survival in the presence of normal coronary arteries. A case report. *Angiology* 1996;47:295–7.
- 7 Viveiros Monteiro A, Galrinho A, Moura Branco L, et al. Multiple mechanical complications in ST-segment elevation myocardial infarction with angiographically normal coronary arteries. Rev Port Cardiol 2015;34:209.e1–209.e3.
- 8 Akilli H, Alibasic H, Kayrak M, et al. Normal coronary myocardial infarct is innocent or guilty? A case of ventricular septal rupture secondary to normal coronary myocardial infarction. J Cardiol Cases 2013;8:187–9.
- 9 Rodríguez Muñoz D, Alonso Salinas G, Pastor Pueyo P, et al. Ventricular septal rupture in a case of myocardial infarction with normal coronary arteries: case report. Rev Port Cardiol 2016;35:63.e1–63.e5.
- 10 Binetti G, Maresta A, Piovaccari G, et al. [Rupture of interventricular septum and ventricular aneurysm secondary to acute myocardial infarction in a case with normal coronary arteries (author's transl)]. G Ital Cardiol 1981;11:144–50.
- 11 Mendes L, Raposo L, Estefania-Fernandez R, et al. Myocardial infarction without obstructive coronary disease complicated by ventricular septal rupture. Rev Port Cardiol 2008;27:859.
- 12 Richardson JV, Niess GS. Ventricular septal rupture with "normal" coronary arteries. Tex Heart Inst J 1985;12:93–6.
- 13 Anchisi C, Rossi L, Bellacosa I, et al. [An unusual case of postinfarction ventricular septal rupture in a patient with angiographically normal coronary arteries]. G Ital Cardiol 2014:15:330–4.
- 14 Assenza GE, McElhinney DB, Valente AM, et al. Transcatheter closure of postmyocardial infarction ventricular septal rupture. Circ Cardiovasc Interv 2013;6:59–67.

Case report

- 15 Calvert PA, Cockburn J, Wynne D, *et al*. Percutaneous closure of postinfarction ventricular septal defect. *Circulation* 2014;129:2395–402.
- 16 Thiele H, Kaulfersch C, Daehnert I, et al. Immediate primary transcatheter closure of postinfarction ventricular septal defects. Eur Heart J 2009:30:81–8.
- 17 Arnaoutakis GJ, Zhao Y, George TJ, et al. Surgical repair of ventricular septal defect after myocardial infarction: outcomes from the Society of thoracic surgeons national database. Ann Thorac Surg 2012;94:436–44.
- 18 Serpytis P, Karvelyte N, Serpytis R, et al. Post-Infarction ventricular septal defect: risk factors and early outcomes. Hellenic J Cardiol 2015;56:66–71.

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ► Submit as many cases as you like
- ► Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ► Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow